您当前所在的位置:首页 > 产品中心 > 产品信息
Flurazepam_分子结构_CAS_17617-23-1)
点击图片或这里关闭

Flurazepam

产品号 DB00690 公司名称 DrugBank
CAS号 17617-23-1 公司网站 http://www.ualberta.ca/
分子式 C21H23ClFN3O 电 话 (780) 492-3111
分子量 387.8782232 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 572

产品价格信息

请登录

产品别名

标题
Flurazepam
IUPAC标准名
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
IUPAC传统名
flurazepam
商标名
Noctosom
Dalmane
Valdorm
Somnol
Felison
Felmane
Flunox
Insumin
Paxane
Stauroderm
Dalmadorm
别名
Flurazepam HCL

产品登记号

PubChem CID 3393
CAS号 17617-23-1
PubChem SID 46508451

产品性质

疏水性(logP) 3.8
溶解度 500 mg/mL (HCl salt)

产品详细信息

详细说明 (English)
Item Information
Drug Groups illicit; approved
Description A benzodiazepine derivative used mainly as a hypnotic. [PubChem]
Indication For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
Pharmacology Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
Toxicity Coma, confusion, low blood pressure, sleepiness
Affected Organisms
Humans and other mammals
Biotransformation Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form
Absorption Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Half Life The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
Protein Binding 83%
Elimination Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
References
[Link]
Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [Pubmed]
Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [Pubmed]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed]
Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [Pubmed]
Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. Pubmed
  • Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. Pubmed
  • Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
  • Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. Pubmed
  • Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. Pubmed
  • Link